Atezolizumab plus bevacizumab versus TACE for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign an informed consent form
- Your liver cancer (HCC) is confirmed by tumor tissue or a typical CT/MRI scan
- Your cancer is “intermediate stage”: it’s not treatable by cure surgery/ablation, but it is treatable with TACE at enrollment (as your doctor decides)
- Your liver is working well enough: Child-Pugh class A or B7 (and ascites must not be a major problem)
- Your overall health is good enough: ECOG 0–1 and you have blood test results within required ranges
- Your stomach veins (varices) have been checked and treated if needed to lower bleeding risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This Phase 2 trial tests whether atezolizumab plus bevacizumab, given along with liver cancer treatment procedures (TACE/HAIC), can help people with advanced liver cancer that cannot be removed by surgery. It mainly looks at whether these medicines can control the cancer more effectively and safely.
This trial tests giving a low dose of two drugs (bevacizumab and atezolizumab) alongside standard local treatments (TACE and HAIC) for liver cancer that cannot be removed with surgery. The goal is to see if this combination helps control the tumor better or improves outcomes.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial studies whether adding atezolizumab and bevacizumab after complete liver cancer surgery can lower the chance the cancer comes back. It also uses “multi-omics” tests (special lab tests on your tissue/blood) to help predict who is more likely to respond or resist treatment.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.